The presented studies in Table 1 included patients diagnosed with various types of cancer, such as Ewing sarcoma, renal cell carcinoma, lung adenocarcinoma, malignant melanoma, cutaneous malignancies, urothelial carcinoma, and advanced gastric cancer treated with various ICIs, including CTLA-4 Inhibitor (ipilimumab drug), PD-1 inhibitors (toripalimab, nivolumab, and pembrolizumab drugs), and PD-L1 inhibitors (atezolizumab drug) highlighting a range of cancer types and treatments associated with hypogonadism and other endocrine disorders. This evidence concerns the gene CTLA4 and endocrine system disorder.